2. Academic Validation
  3. IS-741 (Ishihara Sangyo)

IS-741 (Ishihara Sangyo)

  • Curr Opin Investig Drugs. 2001 Apr;2(4):510-2.
C Bassi 1
Affiliations

Affiliation

  • 1 Surgical and Gastroenterological Department, University of Verona, Hospital GB Rossi, Verona, Italy. [email protected]
PMID: 11566008
Abstract

IS-741 is a Phospholipase A2 (PLA2) inhibitor under development by Ishihara Sangyo Kaisha and Sumitomo as a potential treatment for pancreatitis 1187575]. Sumitomo is developing the drug in phase II trials for acute pancreatitis 13990261. In an animal model, IS-741 has been shown to prevent pancreatitis-associated lung injury following endotoxemia [337503].

Figures
Products